Under the leadership of , the Alzheimer’s Prevention Program is the leading voice on the integrative clinical approach to risk reduction of Alzheimer’s disease. Our mission is to reduce the risk of Alzheimer’s disease (AD) and other neurodegenerative dementias while advancing research in the field. 
Our approach is based on a collaborative care model for Alzheimer's disease, while being firmly grounded in the latest scientific evidence-based therapies. This integrated approach to care aims to provide the most comprehensive therapies for patients with Alzheimer's disease, mild cognitive impairment due to Alzheimer's, "preclinical" Alzheimer's, and patients who are at risk for the disease.